APLI — Appili Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- CA$3.64m
- CA$11.05m
- CA$0.33m
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.199 | 0 | 1.39 | 0.334 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 6.54 | 6.29 | 15.7 | 26 | 8.25 |
Operating Profit | -6.54 | -6.09 | -15.7 | -24.6 | -7.91 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.33 | -5.42 | -14.3 | -25.1 | -9.21 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.33 | -5.42 | -14.3 | -25.1 | -9.24 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.33 | -5.42 | -14.3 | -25.1 | -9.24 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.33 | -5.42 | -14.3 | -25.1 | -9.24 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.129 | -0.158 | -0.242 | -0.376 | -0.081 |
Dividends per Share |